

REMARKS

The specification has been preliminarily amended to recite claims to priority based on previously filed parental applications. No new matter has been added to the application via this amendment to the specification.

Claims 28-31 and 40-50 are pending examination in this application. Claims 1-27 and 32-39 have been canceled without prejudice or disclaimer. New claims 40-50 have been added. Applicants have preliminarily amended claims to better define methods of treating and/or preventing diseases. Support for the amendments to the claims can be found throughout the application as filed. In particular, support for amended claim 28 can be found in the specification at page 9, line 17- page 14, line 26. Amended claims 29-31 find support in the specification at page 13, lines 21 –34.


New claims 40, 41, 45 and 46 find support in the specification at page 12, lines 4-19. Support for new claims 42, 43, 47 and 48 can be found in the specification at page 3, lines 26-35; page 12, line 21 through page 13, line 3; and page 15, lines 12-17. New claims 44 and 50 find support in the specification at page 7, lines 21-23; page 9, lines 13-24 and page 13, lines 17-34. Applicants respectfully submit that no new matter has been introduced into the application via these amendments to the claims.

An early and favorable Action on the merits is respectfully requested. Should any questions regarding the patentability of the claims arise, the Examiner is invited to telephone the undersigned to discuss the same.

Respectfully submitted,

PILLSBURY WINTHROP LLP

JSB/BET/lmr
1600 Tysons Boulevard
McLean, Virginia, 22102
Tel.: (703) 905-2000

By: 
Blair Elizabeth Taylor, Ph.D.
Reg. No. 44,370
Tel: (703) 905-2198
Fax: (703) 905-2500

APPENDIX
MARK UP VERSION SHOWING CHANGES MADE

IN THE CLAIMS:

The claims have been amended as indicated below.

28. (Amended) A method of treating, preventing or treating and [and/or] preventing a disease in a human or an animal comprising administering a pharmaceutically effective amount of a fish serine proteinase,
wherein said disease is a member selected from the group consisting of pain, acute inflammation, chronic inflammation, arthritis, inflamed joints, bursitis, osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, septic arthritis, fibromyalgia, systemic lupus erythematosus, phlebitis, tendinitis, rash, psoriasis, acne, eczema, facial seborrheic eczema, eczema of the hands, face or neck, foreskin infections, athlete's foot, fistulae infections, infected topical ulcers, navel infections in newborns, wrinkles, scars, keloids, boils, warts and allergic itch, hemorrhoids, wounds, wound infections, wounds from burns and a fungal infection.

29. (Amended) The [A] method according to claim 28, wherein the proteinase is a trypsin [proteinase according to any of claims 2-11].

30. (Amended) The [A] method according to claim 28, wherein the proteinase is administered topically.

31. (Amended) The [A] method according to claim 28, wherein the proteinase is administered gastroenterally.